CTEV Claritev Corporation
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services. It also provides data and analytics solutions consists of PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services. The company provides solutions to commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies and other companies involved in the claims adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.…
Industry Peers
Health Information ServicesKey Statistics
About Claritev (NYSE: CTEV)
›
Claritev (NYSE: CTEV) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 3,000 employees.
The shares were at 18.28 USD on 20 November 2026, down 52.1% over 52 weeks. Its 52-week range is 11.50 USD to 55.50 USD: the price is 67.1% below the high and 59.0% above the low.
Its market capitalisation is 312.13M USD.
Claritev reports return on equity of 163.5%, an operating margin of 9.5% and revenue up 9.1% year over year.
Its debt exceeds its cash by 4.72B USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 48.60 USD is 165.9% above the current price. The next earnings report is expected on 23 February 2027.